Becoming the World’s Most Competitive ATMP Region – Through Collaboration, Innovation, and Infrastructure

As Advanced Therapy Medicinal Products (ATMPs) transform modern medicine with their potential to treat, and even cure, a range of previously untreatable conditions, the need to create a solid foundation for their development, regulation, production, and clinical application has never been more pressing. The Medicon Valley region, with its cross-border strengths in life science research, innovation, and collaboration, is in a unique position to take a leading role in this transformation.

At this meeting, we will bring together key stakeholders from research and industry to explore and discuss how we can advance the region’s ATMP ecosystem.

The programme will address the importance of:

• Production infrastructure, both for research and clinical pilot studies, for reliable supply to large trials, and to the market after approval
• The required education and competences that equip future professionals across disciplines to work effectively within the ATMP field.
• The regulatory landscape – both how it is evolving while the field is progressing, and how current regulations shape clinical trials in the ATMP area.

An expert panel will discuss how we can strengthen collaboration across sectors and borders to realize our shared vision: making Medicon Valley the most competitive ATMP region in the world.

Join us for an engaging meeting.

Date: Thursday 18th September 2025
Time: 14:00 – 18:00
Venue: Medicon Valley Alliance, HUB2, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Auditorium

SIGN UP

Program:

Speakers​​​​

	Sara Nolbrant is the project manager for the LU ATMP Pre-GMP facility at Lund University, with the mission to help accelerate the development on new ATMPs and bridge the gap between university and hospital. She earned her PhD in at Lund University, where she worked on developing a cell replacement therapy for Parkinson’s disease, and she gained postdoctoral training from UCSF and experience as a scientific consultant within cell therapy development in the US.
	Ulrik Cordes is the Founder and Chief Executive Officer of Cbio A/S, a company that is dedicated to developing and bringing cell-based ATMPs faster to patients worldwide. Cbio has its own facility for producing ATMPs for clinical trials and has recently finalized the preclinical development for a novel T-cell therapy product against cervical cancer in collaboration with Karolinska Hospital.
	Christoffer Egeberg Hother is a medical doctor, specialist in clinical immunology, and Ph.D. with expertise in clinical bioinformatics and advanced therapies. He is a Senior Advisor in Amgros and part of ATMP Denmark, drawing on experience in national implementation of genomic medicine, regulatory frameworks, and health data infrastructures across the healthcare system.
	Özcan Met is heading the Cell Therapy Unit at the National Center for Cancer Immune Therapy, Denmark since 2010, directing all operational activities required for the manufacturing of cellular products intended for use in clinical trials. As Head of Cell Therapy, he has been responsible for the release of more than 200 cell therapy products in phase I, II, and III immunotherapy clinical trials. He has more than 20 years of research experience in tailoring the immune system to combat cancer and is leading a team at the cutting edge in the development of novel cell-based technologies for patient treatment.
	Johan Flygare is an MD PhD, leading a research group at Lund Stem Cell Center focusing on identifying key regulators of red blood cell development and developing novel therapies for bone marrow failure and anemia. He is the Director of the Swedish National Research School in Advanced Therapies and co-founder of the gene therapy company Apriligen.
	Mattias Magnusson is an Associate Professor of Molecular Medicine at Lund University, where his research focuses on developing stem cell-based therapies for lung diseases. He coordinates the Research School in Stem Cell Biology at the Lund Stem Cell Center and is the Director of the international doctoral programme RAMP-UP, which trains PhD students in advanced therapies and regenerative medicine across academia, healthcare, and industry.
	Sara Falkenklint, Senior Consultant and Trainer at GBA Key2Compliance, has held quality roles in the pharmaceutical industry since 2006, with recent years focused on ATMPs. Within the field of cell and gene therapy, she has delivered trainings and provided support to both small organizations, operating under hospital exemption and larger companies in clinical and commercial phases across the Nordic region.
	Gisela Helenius is the director for the newly established center for Advanced Therapy Medicinal Products, the ATMP center at Skåne University Hospital in Lund. The ATMP center in Lund is working to accelerate the patient access to new ATMPs by facilitating the processes of bringing translational research into clinical trials.
	Niels B. Larsen is a Professor at DTU Health Tech specializing in advanced microengineering for cell and tissue culture in industrial and clinical applications. Niels also coordinates DTU’s educational initiative in cell-based therapy manufacturing, training engineers to bridge the gap from research to product.
	Jette Østergaard Rathe is a medical doctor and Ph.D. with expertise in evidence-based medicine and advanced therapies. She is Senior Medical Advisor in Amgros and Head of Medical Collaboration in ATMP Denmark, drawing on experience in drug evaluation, outcome-based agreements, and implementation of hospital medicines across the healthcare system.
	Bo Wiinberg is Chief Business Development Officer at the Novo Nordisk Foundation Cellerator, leading strategic partnerships and innovation to advance advanced therapies. With experience across academia, biotech, and pharma—including senior roles at Novo Nordisk and as Entrepreneur in Residence at the BioInnovation Institute—he focuses on strengthening Nordic and European ATMP infrastructure, fostering regulatory alignment, and accelerating translation from discovery to first-in-human trials.
	Thomas Areschoug has extensive experience of business development, investment promotion and biomedical R&D in the Life Science sector. Thomas has held leading positions at management team level as CBO in Xintela AB and Targinta AB, and has previously led the investment promotion work in Life Sciences at Business Sweden. He has also engaged in board work in biotech, and has worked as consultant and scientific advisor. Thomas holds a PhD in Medical Microbiology from Lund University.

Deadline for registration is 16 September 2025

The MVA R&D Network
Joining the MVA R&D Network is free of charge but is limited to Medicon Valley Alliance members. Non-member organizations and companies are welcome to attend one network event to evaluate the relevance in joining the network.

For more information please contact Katrine Brems Olsen kbo@mva.org

Organized by